Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Plan B Lightning May Strike Again: Compliance May Not End Political Storm

Executive Summary

Perpetual political lightning rod - and emergency contraceptive - Plan B will have more chances to draw strikes to FDA as the agency chooses to comply with a court ruling ordering it to reconsider whether the drug should be available in a truly over-the-counter setting

You may also be interested in...



Ella And Plan B: Complementary, Competitive Or Confusion?

HRA Pharma's emergency contraceptive Ella (ulipristal acetate) is effective up to five days after unprotected intercourse or contraceptive failure, overlapping with the three-day efficacy period of Teva's Plan B (levonorgestrel). But whether the result will be harmonious market niche carving or confusion remains to be seen

FDA Needs Dispute Resolution Office At Commissioner Level - Internal Report

FDA should create a unit within the commissioner's office dedicated to managing disputes between companies or other entities and the agency's centers, a report by agency staffers says

FDA Needs Dispute Resolution Office At Commissioner Level - Internal Report

FDA should create a unit within the commissioner's office dedicated to managing disputes between companies or other entities and the agency's centers, a report by agency staffers says

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS050998

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel